Methods and compositions for the treatment of steatosis-associated disorders
US12171731B2 · kind B2 · utility
0Cited by
7References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 22, 2023 |
| Grant date | Dec 24, 2024 |
| Priority date | — |
| Expiry date | May 22, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/01076
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to methods of treating a steatosis- associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.